Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05634291 · ClinicalTrials.gov registry record · NA

Effects of the Nottingham Augmented Reality (AR) App for Arthritis Hand Joint Pain

A NA study of Chronic Pain and Opioid Use, sponsored by VRx Medical.

Completed
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT05634291 is a NA study of Chronic Pain and Opioid Use that has completed, run by VRx Medical. The registered enrollment target is 36 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05634291, a NA study of Chronic Pain and Opioid Use, has completed, sponsored by VRx Medical.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The aim of this run-in design, feasibility study is to assess outcomes (including opioid-use, pain intensity, emotional function, and general physical function) for an augmented reality illusion therapy in participants with chronic hand joint pain due to arthritis.

Interventions

  • OTHER Standard of care
  • DEVICE Nottingham AR smartphone app with active intervention

Study Locations (1)

California

  • VA San Diego Healthcare System - San Diego

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2022-06-13
Est. Completion 2023-07-21
Phase NA

Sponsor

VRx Medical

1 total trials

What the Registry Record Tells You About NCT05634291

The ClinicalTrials.gov registry entry for NCT05634291 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (95% lower). The listed sponsor is VRx Medical, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.

NCT05634291 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05634291 about?

NCT05634291 is a clinical study titled "Effects of the Nottingham Augmented Reality (AR) App for Arthritis Hand Joint Pain". The aim of this run-in design, feasibility study is to assess outcomes (including opioid-use, pain intensity, emotional function, and general physical function) for an augmented reality illusion therapy in participants with chronic hand joint pain due to arthritis.

What is the current status of trial NCT05634291?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2022-06-13. Estimated completion is 2023-07-21.

What conditions does trial NCT05634291 study?

This clinical trial studies the following conditions: Chronic Pain, Opioid Use, Arthritis Hand.

What interventions are being tested in trial NCT05634291?

The interventions under investigation include: Standard of care (OTHER), Nottingham AR smartphone app with active intervention (DEVICE).

Who is sponsoring clinical trial NCT05634291?

This trial is sponsored by VRx Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05634291 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.